ibrutinib
abbvie,janssen
['party', 'abbvie']
j&amp;j and abbvie popped the cork on some preliminary data at #asco22 showing imbruvica kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. but will overall survival data crash the party? 
Biopharma reporter @endpts | Previously @LowellSun, @BostonGlobeMag, @DailyHampGaz, @telegramdotcom | @UMassAmherst grad | nicole@endpointsnews.com